Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Roquefort Investments PLC ( (GB:COIL) ).
Coiled Therapeutics has reported strong interim data from its ongoing Phase I/II trial of AO-252, showing an 80% clinical benefit rate and durable disease control exceeding six months in a twice-daily dosing cohort, markedly better than once-daily dosing and typical salvage therapy outcomes in heavily pre-treated solid tumour patients. The drug continues to display a benign safety profile without reaching a maximum tolerated dose, while emerging immune-modulatory activity via the cGAS/STING pathway supports plans to move rapidly into dose expansion in ovarian and prostate cancers, introduce a next-generation formulation, and initiate combination studies in 2026, potentially enhancing its clinical and commercial positioning in oncology.
The most recent analyst rating on (GB:COIL) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Roquefort Investments PLC stock, see the GB:COIL Stock Forecast page.
Spark’s Take on COIL Stock
According to Spark, TipRanks’ AI Analyst, COIL is a Neutral.
The score is primarily held back by weak financial fundamentals (pre-commercial revenue volatility, ongoing losses and cash burn). Technical indicators also point to a sustained downtrend. Low leverage on the balance sheet provides some support, but the negative P/E and lack of dividend yield limit valuation appeal.
To see Spark’s full report on COIL stock, click here.
More about Roquefort Investments PLC
Coiled Therapeutics plc is an AIM-listed, clinical-stage biotechnology company focused on precision oncology therapies for hard-to-treat solid tumours. Its lead programme, AO-252, is a first-in-class, orally administered TACC3 inhibitor in Phase I trials in the U.S., with additional work on a STAT-6 siRNA programme for immunology indications and strategic backing from A2A Pharmaceuticals.
Average Trading Volume: 93,001
Technical Sentiment Signal: Sell
Current Market Cap: £36.2M
See more insights into COIL stock on TipRanks’ Stock Analysis page.